Actively Recruiting
Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-30
50
Participants Needed
3
Research Sites
188 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Observational, Non-Interventional, Retrospective, Multicenter Study Focusing on the Efficacy and Safety of Pembrolizumab Monotherapy and Nivolumab in Combination With Brentuximab Vedotin in Clinical Practice Patients With Primary Mediastinal B Cell Lymphoma Relapsed/Refractory
CONDITIONS
Official Title
Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed diagnosis of relapsed or refractory Primary Mediastinal B Cell Lymphoma treated with pembrolizumab alone or nivolumab with brentuximab vedotin in real-life practice up to November 2021
- Age 18 years or older at enrollment
- Signed written informed consent where applicable
You will not qualify if you...
- Patients treated with pembrolizumab alone or nivolumab with brentuximab vedotin within a clinical trial context
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, Bologna, Italy, 40138
Actively Recruiting
2
Azienda Ospedaliera Universitaria- POLICLINICO BARI
Bari, Italy, 70124
Actively Recruiting
3
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy, 20133
Actively Recruiting
Research Team
P
Pier Luigi Zinzani, MD
CONTACT
C
Cinzia Pellegrini, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here